Age, years, Mean (SD) |  |  | 47 (SD±11) |
   Women |  |  | 48.3 (SD±11) |
   Men |  |  | 44.8 (SD±10.1) |
 |  |  | (P=0.022) |
Civil status, n (%) | Â | Â | Â |
   Married/cohabitant |  |  | 184 (72) |
   Living alone |  |  | 72 (28) |
Education, n (%) | Â | Â | Â |
   Lower: Compulsory - Secondary school |  |  | 168 (66) |
   Higher: After secondary school - University |  |  | 88 (34) |
Occupation, n (%) | Â | Â | Â |
   Work |  |  | 106 (42) |
   Work and part-time retired or on sick leave |  |  | 46 (18) |
   No work |  |  | 103 (40) |
   Missing data (n = 1) |  |  |  |
Age at onset, year, Md (Q1 ; Q3 ) | Â | Â | 31 (25; 38) |
Years since onset of MS symptoms, Md (Q1 ; Q3 ) | Â | Â | 13 (8; 22) |
Course of the disease, n (%) | Â | Â | Â |
   Relapsing - remitting (RR) |  |  | 186 (73) |
   Progressive forms (primary [PP] and secondary progressive [SP]) |  |  | 70 (27) |
Disease severity, n (%) | Â | Â | Â |
   Normal neurological condition, EDSS = 0 |  |  | 26 (10) |
   Mild, 1.0≤EDSS≤ 3.5 |  |  | 157 (61) |
   Moderate, 4.0≤ EDSS≤5.5 |  |  | 30 (12) |
   Severe, 6.0≤ EDSS≤6.5 |  |  | 43 (17) |
Medication, n (%) | Â | Â | Â |
   No pharmacological treatment | 54 (21) |  |  |
   Pharmacological treatment | 202 (79) |  |  |
Immune-modulating treatment | Â | 144 (56) | Â |
β-interferon |  |  | 91 (36) |
glatiramer acetate | Â | Â | 33 (13) |
natalizumab | Â | Â | 20 (8) |
For fatigue | Â | 32 (13) | Â |
modafinil | Â | Â | 32(13) |
amantadinchlorid | Â | Â | 2(0.7) |
Antidepressants | Â | 46 (18) | Â |
Analgesics | Â | 61 (24) | Â |
Spasmolytical treatment | Â | 36 (14) | Â |